research First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
Hasselt, Belgium
Dhaka, Bangladesh
Samsun, Türkiye
Ankara, Türkiye
İzmir, Türkiye
Istanbul, Türkiye
